RYTELO Market Summary

Key Factors Driving RYTELO Growth

1. First-in-class telomerase inhibitor with a differentiated mechanism of action

RYTELO (Imetelstat) is the first and only FDA-approved telomerase inhibitor for adults with low- to intermediate-1 risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia who are refractory to, have lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs). Approved by the FDA in June 2024, RYTELO offers a novel disease-targeting mechanism by inhibiting telomerase activity in malignant hematopoietic progenitor cells, differentiating it from supportive care and erythroid maturation agents. This unique positioning addresses a significant unmet need in ESA-refractory LR-MDS and supports long-term commercial growth.

2. Strong efficacy demonstrated in the pivotal IMerge Phase III trial

The FDA approval was based on the Phase III IMerge trial involving 178 patients with transfusion-dependent LR-MDS. RYTELO achieved the primary endpoint of ≥8-week red blood cell transfusion independence (RBC-TI) in 39.8% of patients, compared with 15.0% in the placebo arm (p<0.001). Furthermore, 28% of patients achieved ≥24-week RBC-TI, versus 3.3% with placebo, demonstrating durable hematologic responses that are clinically meaningful for reducing transfusion burden and improving quality of life. These robust efficacy data are expected to drive physician confidence and broader adoption.

3. Large unmet need in transfusion-dependent lower-risk MDS

Lower-risk MDS affects thousands of patients annually, and anemia is the most common complication. Many patients become chronically dependent on red blood cell transfusions after failing ESAs, leading to iron overload, reduced quality of life, and increased healthcare utilization. RYTELO specifically addresses this underserved patient population regardless of ring sideroblast status, expanding its eligible patient pool compared with some existing therapies. As treatment guidelines increasingly incorporate effective post-ESA options, demand for RYTELO is expected to increase.

4. Potential disease-modifying activity supports long-term differentiation

Unlike therapies that primarily stimulate erythropoiesis, imetelstat targets malignant stem and progenitor cells by inhibiting telomerase, potentially altering the underlying biology of MDS. Clinical and translational analyses from the IMerge program demonstrated reductions in telomerase activity and malignant clone burden in responding patients, suggesting potential disease-modifying effects beyond transfusion reduction. This differentiated mechanism could strengthen physician preference and support future clinical development in additional hematologic malignancies, including relapsed/refractory myelofibrosis.

5. Global regulatory expansion and ongoing lifecycle development

Following U.S. approval, RYTELO received European Commission approval in 2025 for eligible patients with transfusion-dependent lower-risk MDS, substantially expanding its commercial opportunity. Geron is also continuing development through the IMpactMF Phase III trial in relapsed/refractory myelofibrosis, which could significantly broaden the drug's addressable market if successful. Continued geographic expansion and indication development provide important long-term growth catalysts.

RYTELO Recent Developments

In August 2026, Geron Corporation, a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, reported financial results for the second quarter of 2026 and recent business highlights.

• Reported RYTELO net product revenue of $57.5 million in the second quarter of 2026.

o Grew RYTELO demand by 5% in the second quarter 2026, compared to the first quarter 2026.

o Increased ordering accounts by roughly 8% in the second quarter 2026 to approximately 1,575.

• Presented the first real-world evidence study of RYTELO in patients with lower-risk myelodysplastic syndromes (LR-MDS) at the European Hematology Association (EHA) 2026 Congress. The retrospective portion of the investigator-sponsored study, conducted at the Moffitt Cancer Center, reported safety and clinical efficacy of imetelstat in advanced, heavily transfusion-dependent patients with LR-MDS, including patients with extensive prior therapies and after luspatercept failure. The efficacy, safety and tolerability observed were generally consistent with findings from the Phase 3 IMerge trial in a broader patient population.

“RYTELO Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of RYTELO for approved indication like Myelodysplastic syndrome; as well as potential indication like Acute myeloid leukaemia and Myelofibrosis in the 7MM. A detailed picture of RYTELO’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the RYTELO for approved and potential indications. The RYTELO market report provides insights about RYTELO’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current RYTELO performance, future market assessments inclusive of the RYTELO market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of RYTELO sales forecasts, along with factors driving its market.

RYTELO Drug Summary

RYTELO (Imetelstat) is a first-in-class, intravenously administered telomerase inhibitor approved for the treatment of adults with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring regular red blood cell transfusions and who have not responded to, lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is an oligonucleotide that selectively binds to the RNA template component of human telomerase (hTR), inhibiting telomerase activity in malignant hematopoietic progenitor cells, thereby reducing the proliferation of abnormal clones and promoting durable hematologic responses. Administered as an intravenous infusion every four weeks, RYTELO demonstrated clinically meaningful improvements in red blood cell transfusion independence and sustained hemoglobin responses in the pivotal IMerge Phase III trial. The most common adverse events include thrombocytopenia, neutropenia, anemia, fatigue, and elevated liver enzymes, requiring regular hematologic and hepatic monitoring during treatment. Approved by the U.S. FDA in 2024, RYTELO represents the first telomerase inhibitor to reach the market and offers a novel disease-modifying therapeutic option for eligible patients with lower-risk MDS and transfusion-dependent anemia. The report provides RYTELO’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the RYTELO Market Report

The report provides insights into:

• A comprehensive product overview including the RYTELO MoA, description, dosage and administration, research and development activities in approved indications like Myelodysplastic syndrome; as well as potential indication like Acute myeloid leukaemia and Myelofibrosis.
• Elaborated details on RYTELO regulatory milestones and other development activities have been provided in RYTELO market report.
• The report also highlights RYTELO‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The RYTELO market report also covers the patents information, generic entry and impact on cost cut.
• The RYTELO market report contains current and forecasted RYTELO sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The RYTELO market report also features the SWOT analysis with analyst views for RYTELO in approved and potential indications.

Methodology

The RYTELO market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RYTELO Analytical Perspective by DelveInsight

• In-depth RYTELO Market Assessment

This RYTELO sales market forecast report provides a detailed market assessment of RYTELO for approved indication like Myelodysplastic syndrome; as well as potential indication like Acute myeloid leukaemia and Myelofibrosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted RYTELO sales data uptil 2034.

• RYTELO Clinical Assessment

The RYTELO market report provides the clinical trials information of RYTELO for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

RYTELO Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

RYTELO Market Potential & Revenue Forecast

• Projected market size for the RYTELO and its key indications
• Estimated RYTELO sales potential (RYTELO peak sales forecasts)
• RYTELO Pricing strategies and reimbursement landscape

RYTELO Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• RYTELO Market positioning compared to existing treatments
• RYTELO Strengths & weaknesses relative to competitors

RYTELO Regulatory & Commercial Milestones

• RYTELO Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

RYTELO Clinical Differentiation

• RYTELO Efficacy & safety advantages over existing drugs
• RYTELO Unique selling points

RYTELO Market Report Highlights

• In the coming years, the RYTELO market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The RYTELO companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RYTELO’s dominance.
• Other emerging products for Myelodysplastic syndrome; as well as potential indication like Acute myeloid leukaemia and Myelofibrosis are expected to give tough market competition to RYTELO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RYTELO in approved and potential indications.
• Analyse RYTELO cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted RYTELO sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of RYTELO in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of RYTELO? How strong is RYTELO’s clinical and commercial performance?
• What is RYTELO’s clinical trial status in each individual indications such as Myelodysplastic syndrome; as well as potential indication like Acute myeloid leukaemia and Myelofibrosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RYTELO Manufacturers?
• What are the key designations that have been granted to RYTELO for approved and potential indications? How are they going to impact RYTELO’s penetration in various geographies?
• What is the current and forecasted RYTELO market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of RYTELO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to RYTELO for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is RYTELO? What is the duration of therapy and what are the geographical variations in cost per patient?